About the Company
We do not have any company description for Omega Therapeutics, Inc. at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Omega Therapeutics, Inc.
Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings ... - Nasdaq
Wall Street expects a year-over-year increase in earnings on higher revenues when Omega Therapeutics, Inc. (OMGA) reports results for the quarter ended March 2024. While this widely-known ...
Omega Therapeutics, Inc. (OMGA) Reports Q2 Loss, Tops Revenue ... - Nasdaq
Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago. These ...
Omega Therapeutics Reports Second Quarter 2024 ... - Seeking Alpha
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Aug. 06, 2024 7:00 AM ET Omega Therapeutics, Inc. (OMGAQ) ...
OMGAQ - Omega Therapeutics Inc News | Morningstar
Read about Omega Therapeutics Inc (OMGAQ:PINX) stock and today's latest news and financial updates.
OMGAQ - Omega Therapeutics Inc Dividends | Morningstar
Review the current Omega Therapeutics Inc (OMGAQ:PINX) dividend yield and history to decide if OMGAQ is the best investment for you.
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ...
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of ...
Omega Therapeutics Presents New Preclinical Data Supporting the ...
CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of ...
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board ...
CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using mRNA ...
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for ...
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable ...
Omega Therapeutics' Cancer Program Shows Encouraging Anti Tumor ...
Omega Therapeutics Inc (NASDAQ: OMGA) announced preliminary data from the initial two dose level cohorts (n=8) from Part 1 of its Phase 1/2 MYCHELANGELO I study of OTX-2002 in hepatocellular ...
Similar Companies
Loading the latest forecasts...